When you encounter PTSD medication management questions, focus on the evidence-based guidelines for maintenance therapy duration, especially in patients who've achieved stability through combined treatment approaches.

This veteran represents an ideal treatment response - he's completed evidence-based psychotherapy (CPT), achieved symptom remission on sertraline, and maintained functional recovery for a full year. Current PTSD treatment guidelines recommend continuing effective pharmacotherapy for at least 12 months after achieving symptom stability before considering discontinuation. This approach minimizes relapse risk while the patient consolidates therapeutic gains.

Option D is correct because it follows established guidelines: maintain stable patients on effective medication for at least 12 months post-stabilization before attempting a gradual taper. This patient has been stable for one year, so continuing for "at least another 12 months" ensures adequate consolidation time.

Option A is overly conservative - indefinite treatment isn't necessary for all PTSD patients, especially those with good psychotherapy response and stable remission. Option B ignores the synergistic relationship between psychotherapy and pharmacotherapy; completing CPT doesn't eliminate the need for continued medication stabilization. Option C proposes premature discontinuation with inadequate tapering time - stopping effective PTSD medication after only one year of stability significantly increases relapse risk, and 2-4 weeks is too rapid for safe sertraline discontinuation.

Remember: PTSD medication decisions should balance relapse prevention with treatment burden. Stable patients need at least 12 months of continued pharmacotherapy before considering discontinuation, regardless of psychotherapy completion.

The correct answer is C. Risperidone long-acting injectable microspheres (Risperdal Consta) has a delayed onset of action, as the medication is slowly released from the microspheres. Therapeutic plasma concentrations are not reached for approximately 3 weeks after the initial injection. Therefore, oral antipsychotic supplementation (in this case, the patient's current oral risperidone) must be continued for the first 3 weeks to ensure continuous therapeutic coverage and prevent relapse.

The correct answer is B. This patient has had a partial response to an adequate trial (sufficient dose and duration) of an SSRI. In cases of partial response, augmentation is often more effective than switching to another agent within the same class. Atypical antipsychotics like aripiprazole, quetiapine, and brexpiprazole are FDA-approved and evidence-based augmentation agents for major depressive disorder. Switching to another SSRI (A) is a reasonable strategy but generally reserved for non-response or intolerance. Increasing sertraline beyond its maximum recommended dose of 200 mg (C) is not evidence-based and increases the risk of side effects. Adding a benzodiazepine (D) does not target core depressive symptoms and is inappropriate for long-term management.

The correct answer is B. Valproic acid significantly inhibits the metabolism of lamotrigine, more than doubling its serum concentration. To reduce the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), a much slower titration schedule is required when lamotrigine is co-administered with valproate. The recommended starting dose is 25 mg every other day for two weeks. The standard titration (A) is for lamotrigine monotherapy. A faster titration (C, D) would be used with an enzyme-inducing medication (like carbamazepine) but would be extremely dangerous in this patient taking valproate, markedly increasing the risk of a life-threatening rash.

The correct answer is B. Long-term, high-dose benzodiazepine use requires a very slow taper to minimize withdrawal symptoms. A direct taper of a short-acting agent like lorazepam can be difficult due to significant inter-dose rebound anxiety. The preferred method is to switch the patient to an equivalent dose of a long-acting benzodiazepine, such as diazepam or clonazepam. The long half-life of these agents provides a smoother, more gradual decline in blood levels, making the taper more tolerable. A 25% per week taper (A) is too rapid for long-term use. Abrupt cessation (C) can cause severe, life-threatening withdrawal. Switching to another short-acting agent like alprazolam (D) would not facilitate the taper.

The correct answer is C. Management of buprenorphine in the perioperative period requires careful coordination. Buprenorphine is a partial mu-opioid agonist with high receptor affinity, which can interfere with the efficacy of full agonist opioids used for analgesia. While continuing it (A) is one strategy ('continue and override'), a common and effective approach involves holding the buprenorphine for a short period (24-72 hours) before surgery to allow full agonists to work. This must be paired with a robust multimodal pain plan (e.g., regional anesthesia, NSAIDs, acetaminophen) and close monitoring. Stopping it for a prolonged period (B) dramatically increases the risk of withdrawal and relapse. Transitioning to methadone (D) is a complex process not indicated for routine elective surgery.

The correct answer is C. Olanzapine is associated with a high risk of metabolic side effects, including significant weight gain, hyperglycemia, and dyslipidemia. This patient has developed iatrogenic metabolic syndrome. While metformin (A) can be a helpful adjunct, the primary intervention should be to address the offending agent. The most appropriate step is to switch the patient to an antipsychotic with a lower metabolic risk profile, such as ziprasidone, aripiprazole, or lurasidone. Increasing the olanzapine dose (B) would likely worsen the metabolic issues. Bariatric surgery (D) is a significant intervention that may be considered later, but a medication change should be attempted first.

The correct answer is C. The cornerstone of managing borderline personality disorder (BPD) is skills-based psychotherapy (like DBT). A key principle is to avoid reinforcing maladaptive behaviors (e.g., threats of self-harm to obtain medication). The most appropriate response is to validate the patient's emotional pain while simultaneously empowering her to use her previously learned coping skills and crisis plan. Prescribing a benzodiazepine (A) can be dangerous, reinforce dysfunctional behavior, and increase disinhibition. While an ED visit (B) may become necessary if she cannot ensure her safety, the first step is to encourage the use of her established plan. Reactive medication changes (D) are generally ineffective for BPD traits and can destabilize the treatment frame.

When you encounter preconception counseling questions involving psychiatric medications, you need to balance maternal mental health stability against teratogenic risks while considering safer alternatives.

Valproic acid poses significant teratogenic risks, including neural tube defects (1-2% risk), facial dysmorphism, and cognitive impairment in exposed children. For a woman planning pregnancy, continuing valproic acid is inappropriate despite her current stability. The goal is transitioning to a safer mood stabilizer before conception while maintaining psychiatric stability.

Lamotrigine represents the safest mood stabilizer option during pregnancy, with minimal teratogenic risk and effectiveness for bipolar disorder maintenance. A gradual cross-taper allows for smooth transition while monitoring for mood destabilization, making option D correct.

Option A is dangerous because while folic acid reduces neural tube defect risk, it doesn't eliminate valproic acid's other teratogenic effects, and continuing this high-risk medication is unjustifiable when safer alternatives exist.

Option B fails to recognize that untreated bipolar disorder during pregnancy carries substantial risks including poor prenatal care, substance abuse, and postpartum psychosis. Abrupt discontinuation also risks severe mood episodes.

Option C contains a critical misconception - lithium does carry fetal risks, particularly Ebstein's anomaly (though the risk is lower than previously thought, around 0.05-0.1%). While lithium might be considered, lamotrigine remains the preferred first-line option.

Remember: In psychiatric preconception counseling, never choose "stop everything" or continue high-risk medications. Look for the safest effective alternative with proper transition planning.

The correct answer is B. This patient has treatment-resistant OCD, defined as a failure to respond to an adequate trial of a first-line agent (an SSRI at maximum tolerated dose for at least 8-12 weeks) plus ERP. The most evidence-based next step is to augment the SSRI with an atypical antipsychotic, such as risperidone or aripiprazole. Switching to clomipramine (A), a tricyclic antidepressant, is another option, but augmentation is often preferred to preserve the partial response from the SSRI. Increasing the fluoxetine dose beyond the typical maximum (C) is not evidence-based. Augmentation with buspirone (D) has limited evidence for OCD.